Dalfampridine, Ampyra*, to improve walking difficulties in patients with multiple sclerosis
| Author : Pierre Allain
||Date : 2010-1-30
The FDA (January 2010) approved Ampyra*, dalfampridine, for improving walking in patients with multiple sclerosis.
Dalfampridine is another name of fampridine or 4-aminopyridine already introduced in Pharmacorama.
Ampyra* is a slow-release preparation. The dosage recommended is 10 mg twice daily. An overdose can cause seizures.